Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of February 2026. The filing, dated February 19, 2026, serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Form S-8. The registrant is a foreign private issuer based in Mechelen, Belgium.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.

Material Changes

No material financial changes versus a prior comparable period are disclosed in the text of this filing. The content is limited to the announcement of the press release and its incorporation by reference.

Guidance, Outlook, and Risks

The filing references a press release containing quotes from Jérôme Contamine and Henry Gosebruch, but the text of the press release itself is not included in the provided input. Consequently, no specific guidance, outlook, management commentary, risks, contingencies, or unusual items can be summarized from this document alone.

Key Facts for Investor Verification

  • Verify the actual content of the press release (Exhibit 99.1) referenced in this filing, as the summary text does not contain the news details.
  • Confirm the correct registrant name is Galapagos NV, noting a discrepancy with the provided metadata company name.
  • Check the company's Form 20-F filings for the most recent audited financial data, as this 6-K contains no financial metrics.
  • Review the specific quotes from Jérôme Contamine and Henry Gosebruch in the attached exhibit for strategic updates.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.